We improve patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Taking a ground-breaking technology that dramatically improves the information that can be extracted from histological images, Nobel Laureate Dr. Gerd Binnig founded Definiens in 1994. The goal? To create new opportunities for discovery and advances in oncology and immuno-oncology. Since then, Definiens technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 650 peer-reviewed publications. In 2013, Frost and Sullivan recognized Definiens as Company of the Year for Global Tissue Diagnostics and Pathology Imaging.
Definiens is now an international company with over 100 employees worldwide, and headquartered in Munich, Germany and Cambridge, USA.
Customized analysis of cell status, cell-to-cell dynamics and tissue context of biomarkers unlocks a deeper understanding of cancer. We quantify these features during assay development and the resulting insights drive confident pipeline decisions for clinical trials. Our scientific, regulatory and medical team support you throughout the process. Our services include:
- Biomarker screening to identify the indication of most impact - Evaluation of drug response profiles for pharmacodynamics studies - Exploratory studies with custom assays and quantitative readouts to support regulatory filing
Assessing the potential of a biomarker to identify patient populations requires correlating patient data with drug responses. Using Tissue Phenomics, we mine data from your tissue samples to find meaningful signatures that link ‘omics data with clinical outcomes and generate insights beyond the scope of other approaches. We offer:
- Data-rich biomarker readouts from histological slides of any tissue - Development and evaluation of the most impactful signature candidates - Unique mining of tissue, ‘omics, outcomes, medical history and other data
Certainty is the hallmark of next-generation diagnostics. Our precise quantitative biomarker readouts and best-in-class assay development in accordance with our certified quality management system, build certainty into your CDx. Our scientific and regulatory teams help design the best strategy to advance your prototype to regulatory filing and into the clinic. We support you with:
Definiens, Inc. has not received any reviews.
Definiens, Inc. has not received any endorsements.